Rheumatologic symptoms in oncologic patients on PD-1 inhibitors.

Published on Oct 30, 2017in Seminars in Arthritis and Rheumatism4.751
· DOI :10.1016/J.SEMARTHRIT.2017.10.018
Wilson Kuswanto6
Estimated H-index: 6
(Harvard University),
Lindsey A. MacFarlane14
Estimated H-index: 14
(Harvard University)
+ 3 AuthorsBonnie L. Bermas26
Estimated H-index: 26
(Harvard University)
Sources
Abstract
Abstract Objective Immune checkpoint inhibitors are effective cancer therapies that have been associated with immune-related adverse events (irAEs). Recent reports of irAEs describe symptoms resembling classic rheumatologic syndromes, most notably associated with cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) inhibitor blockade. Though cases have been described, there are fewer reports of rheumatologic disease associated with programmed cell death protein-1 (PD-1) inhibitors. Here, we describe a series of four patients presenting to the Brigham and Women’s Hospital (BWH) Arthritis Center with de novo polymyalgia rheumatica (PMR)-type conditions and/or peripheral synovitis after treatment with PD-1/PD-Ligand 1 (PD-L1) pathway inhibitors. Methods Patients with metastatic renal cell carcinoma (RCC) who were treated with PD-1/PD-L1 pathway inhibitors and subsequently developed complaints of new joint pain were referred to the BWH Arthritis Center as part of routine care and identified retrospectively. The electronic medical record was reviewed for cancer history and treatment, rheumatologic symptoms, physical exam, laboratory testing, and clinical course. Results All four patients developed irAEs consistent with a PMR-type syndrome and/or peripheral synovitis. Symptoms persisted despite discontinuation of the PD-1/PD-L1 pathway inhibitors; however, three of the patients responded well to oral glucocorticoids alone while one patient required the addition of oral methotrexate. All patients had an eventual decline in inflammatory markers. Conclusion These cases highlight the need for both oncologists and rheumatologists to recognize the development of rheumatologic disease during treatment with immune checkpoint blockade. Further investigation is needed to optimize the management of irAEs, particularly considering the increasing use of checkpoint inhibitors to treat malignancies.
📖 Papers frequently viewed together
117 Citations
136 Citations
170 Citations
References16
Newest
#1Juan Martin-Liberal (Hebron University)H-Index: 16
#2Maria Ochoa de Olza (Hebron University)H-Index: 11
Last. Josep Tabernero (Hebron University)H-Index: 118
view all 6 authors...
Abstract The use of agents able to modulate the immune system to induce or potentiate its anti-tumour activity is not a new strategy in oncology. However, the development of new agents such as immune checkpoint inhibitors has achieved unprecedented efficacy results in a wide variety of tumours, dramatically changing the landscape of cancer treatment in recent years. Ipilimumab, nivolumab, pembrolizumab or atezolizumab are now standard of care options in several malignancies and new indications a...
66 CitationsSource
#1Hui Zhang (Stanford University)H-Index: 23
#2Ryu Watanabe (Stanford University)H-Index: 19
Last. Cornelia M. Weyand (Stanford University)H-Index: 132
view all 8 authors...
Abstract Giant cell arteritis (GCA) causes autoimmune inflammation of the aorta and its large branches, resulting in aortic arch syndrome, blindness, and stroke. CD4+ T cells and macrophages form organized granulomatous lesions in the walls of affected arteries, destroy the tunica media, and induce ischemic organ damage through rapid intimal hyperplasia and luminal occlusion. Pathogenic mechanisms remain insufficiently understood; specifically, it is unknown whether the unopposed activation of t...
109 CitationsSource
#1Deepak A. Rao (Brigham and Women's Hospital)H-Index: 22
#2Michael F. Gurish (Brigham and Women's Hospital)H-Index: 59
Last. Michael B. Brenner (Harvard University)H-Index: 124
view all 28 authors...
The authors identify in patients with rheumatoid arthritis a pathogenic subset of CD4+ T cells that augments B cell responses within inflamed tissues.
394 CitationsSource
496 CitationsSource
#1Laura C. Cappelli (Johns Hopkins University)H-Index: 17
#2Anna Kristina Gutierrez (Johns Hopkins University)H-Index: 5
Last. Clifton O. Bingham (Johns Hopkins University)H-Index: 64
view all 13 authors...
Objectives Immune checkpoint inhibitors (ICIs) targeting the cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and programmed cell death protein 1 (PD-1) pathways have demonstrated survival improvements in multiple advanced cancers, but also cause immune-related adverse events (IRAEs). IRAEs with clinical features similar to rheumatic diseases have not been well described. We report patients with inflammatory arthritis and sicca syndrome secondary to ICIs. Methods We report patients evaluated...
227 CitationsSource
Immune checkpoint inhibitors have improved clinical outcomes associated with numerous cancers, but high-grade, immune-related adverse events can occur, particularly with combination immunotherapy. We report the cases of two patients with melanoma in whom fatal myocarditis developed after treatment with ipilimumab and nivolumab. In both patients, there was development of myositis with rhabdomyolysis, early progressive and refractory cardiac electrical instability, and myocarditis with a robust pr...
914 CitationsSource
#1Sarah Law-Ping-ManH-Index: 1
#2Antoine MartinH-Index: 41
Last. Gilles SafaH-Index: 9
view all 5 authors...
46 CitationsSource
#1Claire F. Friedman (Cornell University)H-Index: 14
#2Tracy A. Proverbs-Singh (Cornell University)H-Index: 1
Last. Michael A. Postow (Cornell University)H-Index: 75
view all 3 authors...
Importance The development of immune checkpoint inhibitors targeting cytotoxic T-lymphocyte antigen 4 (CTLA-4) and programmed cell death-1 (PD-1) has significantly improved the treatment of a variety of cancers and led to US Food and Drug Administration approvals for patients with a variety of malignant neoplasms. Immune checkpoint inhibitors enhance antitumor immunity by blocking negative regulators of T-cell function that exist both on immune cells and on tumor cells. Although these agents can...
401 CitationsSource
#1Guillermo de Velasco (Harvard University)H-Index: 22
#2Boonie Bermas (Brigham and Women's Hospital)H-Index: 1
Last. Toni K. Choueiri (Harvard University)H-Index: 116
view all 3 authors...
60 CitationsSource
#1Troy Z. Horvat (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 7
#2Nelly G. Adel (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 11
Last. Paul B. ChapmanH-Index: 74
view all 13 authors...
Purpose Ipilimumab is a standard treatment for metastatic melanoma, but immune-related adverse events (irAEs) are common and can be severe. We reviewed our large, contemporary experience with ipilimumab treatment outside of clinical trials to determine the frequency of use of systemic corticosteroid or anti-tumor necrosis factor α (anti-TNFα) therapy and the effect of these therapies on overall survival (OS) and time to treatment failure (TTF). Patients and Methods We reviewed retrospectively th...
601 CitationsSource
Cited By30
Newest
#1Stephan R. Thurau (LMU: Ludwig Maximilian University of Munich)H-Index: 22
#2Hendrik Engelke (LMU: Ludwig Maximilian University of Munich)H-Index: 1
Last. Gerhild Wildner (LMU: Ludwig Maximilian University of Munich)H-Index: 25
view all 15 authors...
Purpose: New tumor therapies like immune checkpoint inhibitors and small molecule inhibitors of MEK and BRAF have increased the patient's survival rate but can be burdened with severe side-effects including uveitis. Here, we show the spectrum, treatment, and outcome of uveitis types induced by tumor treatment.Methods: In this retrospective study, we have included 54 patients from different centers who were developing uveitis under tumor therapy. A 16-item questionnaire was analyzed for type, tre...
1 CitationsSource
#1Toshiyuki KitaH-Index: 15
#2Tomoyuki ArayaH-Index: 7
Last. Kazuo Kasahara (Kanazawa University)H-Index: 28
view all 6 authors...
Abstract A 79-year-old woman was diagnosed with stage IV (cT1aN1M1, OSS) lung adenocarcinoma with bone metastasis of the right femur. She received nivolumab as a third-line treatment. She developed pain in the right shoulder, left wrist, right knee, and waist as well as a low-grade fever and morning stiffness, after five courses of nivolumab. After closer examination, she was diagnosed with polymyalgia rheumatica (PMR) precipitated by an immune-related adverse event. Nivolumab was discontinued, ...
Source
#1Tomohiro Murakawa (Kansai Medical University)H-Index: 23
Over a half-century has passed since Thomford et al. proposed the selection criteria for pulmonary metastasectomy, and several prognostic factors have been identified. Although screening modalities and operations have changed dramatically, the important concepts of the selection criteria remain unchanged. Recent improvements in the survival outcomes of colorectal cancer patients undergoing pulmonary metastasectomy may be the result of strict adherence to the selection criteria for oligometastati...
2 CitationsSource
#1Carolina Lopes (UBI: University of Beira Interior)
#2S Morgado (Hospital Center of Cova da Beira)H-Index: 2
Last. Manuel MorgadoH-Index: 11
view all 5 authors...
Immune checkpoint inhibitors are a revolution in cancer treatment, having a better toxicity profile than chemotherapy. However, many mechanisms and management of immune-related adverse events are still unknown, and guidelines are a crucial tool to take clinical decisions. However, even the most recent guidelines lack information about alternative treatments for steroid-refractory immune-related adverse events, safety in special populations, biomarkers and therapy reinstitution. The aim of this a...
Source
#1Savino Sciascia (UNITO: University of Turin)H-Index: 34
#2Marie Hudson (JGH: Jewish General Hospital)H-Index: 54
Last. Michael MahlerH-Index: 2
view all 5 authors...
Abstract Immune checkpoint inhibitors (ICI) have dramatically improved the treatment of certain types of cancer and represent an example of applied precision medicine (PM). However, some patients treated with ICI can develop immune-related adverse events (irAE) that can progress to overt life-threatening diseases. During the past years, there have been a flood of case reports and case series reporting irAE mimicking almost every know autoimmune disease. The present chapter summarizes the knowled...
Source
#1Yuli Guzman-PradoH-Index: 3
#2Jennifer Ben Shimol (TAU: Tel Aviv University)H-Index: 2
Last. Ondrej SamsonH-Index: 3
view all 3 authors...
BACKGROUND As a result of the growing use of immune checkpoint inhibitors (ICIs) for treating malignancy, immune-related adverse events (irAEs) have been increasingly reported. Higher body mass index (BMI) has been highlighted as a potential risk factor for the development of irAEs. However, there are no meta-analyses summarizing the association between BMI and irAEs in patients on ICI therapies. METHODS PubMed, MEDLINE, EMBASE, Cochrane and grey literature were searched up to January 2020. Odds...
8 CitationsSource
#1Marie KostineH-Index: 14
#2Axel FinckhH-Index: 54
Last. Thierry SchaeverbekeH-Index: 56
view all 23 authors...
Background Rheumatic and musculoskeletal immune-related adverse events (irAEs) are observed in about 10% of patients with cancer receiving checkpoint inhibitors (CPIs). Given the recent emergence of these events and the lack of guidance for rheumatologists addressing them, a European League Against Rheumatism task force was convened to harmonise expert opinion regarding their identification and management. Methods First, the group formulated research questions for a systematic literature review....
27 CitationsSource
#1Laura C. Cappelli (Johns Hopkins University)H-Index: 17
#2Clifton O. BinghamIII (Johns Hopkins University)
Immune checkpoint inhibitors (ICI) cause a variety of adverse events due to increased immune activation. Inflammatory arthritis is the most common side effect of ICIs seen by rheumatologists. Inflammatory arthritis can have heterogeneous presentations, but, most commonly, presents as an oligoarthritis or polyarthritis. Tendons may also be involved, and imaging shows a variety of changes, including synovitis, joint effusions, tenosynovitis, enthesitis, tendinitis, and enthesophytes. Treatments in...
Source
#1Foteini Angelopoulou (University of Patras)H-Index: 1
#2Dimitrios P. Bogdanos (RMIT: RMIT University)H-Index: 54
Last. Dimitrios Daoussis (University of Patras)H-Index: 22
view all 5 authors...
Immune checkpoint inhibitors (ICI) associate with a wide range of immune-related adverse events (Ir-AE), including musculoskeletal manifestations. We aimed at identifying all studies reporting musculoskeletal Ir-AE. An electronic (Medline, Scopus and Web of Science) search was performed using two sets of key words. The first set consisted of: arthritis, musculoskeletal, polymyalgia rheumatica and myositis. The second set consisted of: anti-PD-1, anti-PD-L1, anti-CTLA-4, ipilimumab, tremelimumab,...
2 CitationsSource
#1Ciro ManzoH-Index: 7
#2Marco Isetta (Central and North West London NHS Foundation Trust)H-Index: 3
Last. Alberto CastagnaH-Index: 12
view all 4 authors...
Background: Polymyalgia Rheumatica (PMR) is one of the most frequent rheumatologic immune-related adverse effects (IRAEs) in cancer patients following therapy with immune checkpoint inhibitors (ICIs). Atypical findings in many patients often lead to diagnosing PMR-like syndromes. Materials and methods: The aim of our research was to review reported diagnoses of PMR and PMR-like syndromes following ICIs therapy, and assess whether they can be redefined as adverse drug reaction (ADR). In line with...
2 CitationsSource